Aerska

Executive Summary

Aerska is a Dublin-based biotechnology company pioneering targeted RNA medicines for brain diseases, leveraging RNA interference (RNAi) technology to silence harmful genes and preserve cognitive function. Founded in 2011, the company has advanced to Phase 2 clinical development, focusing on systemic administration with proprietary brain delivery technologies. Its approach addresses significant unmet needs in neurodegenerative disorders, offering potential disease-modifying therapies. While specific financial details are undisclosed, Aerska's progress in the RNAi space positions it as a notable player in targeted central nervous system (CNS) therapeutics. The company's strategy combines next-generation RNAi with enhanced delivery, aiming to overcome key barriers in brain drug development. With several candidates in the pipeline, Aerska is poised for potential value inflection points as it generates clinical data.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 clinical data readout for lead candidate60% success
• Q4 2026Strategic partnership or licensing deal for CNS delivery platform50% success
• Q2 2027Series C or later-stage financing round to fund pivotal trials70% success